Paper 13 - CONGRATS: A RANDOMIZED PHASE II STUDY OF NIVOLUMAB ± RELATLIMAB IN PATIENTS WITH TLS-POSITIVE ADVANCED SOFT-TISSUE SARCOMAS

Author(s)

• 

  Antoine Italiano, MD, PhD

  Head
  Department of Medicine, Institut Bergonié
  Bordeaux, Aquitaine, France

  Slides

Co-Author(s)

• BV

  Benjamin Verret, MD

  Gustave roussy
  Paris, Ile-de-France, France
• MT

  Maud Toulmonde, MD,PhD

  INSTITUT BERGONIE
  BORDEAUX, Aquitaine, France
• JG

  Jean-Philippe Guegan, PHD

  EXPLICYTE
  BORDEAUX, Aquitaine, France
• 

  Jean-Yves Blay, MD, PhD

  Président UNICANCER, Director of Public Policy ESMO, General Director
  Centre Léon Bérard
  Lyon, Rhone-Alpes, France
• EB

  Emmanuelle Bompas, MD

  Dr
  Institut de Cancerologie de l'Ouest
  Nantes, Pays de la Loire, France
• MS

  Mariella SPALATO CERUSO, MD, PhD (she/her/hers)

  MD, PhD
  Institut Bergonié
  Bordeaux, Aquitaine, France
• FP

  FLORENT PEYRAUD, MD,PhD

  INSTITUT BERGONIE
  BORDEAUX, Aquitaine, France
• HF

  Herve Fridman, MD,PhD

  Professor Emeritus
  CENTRE DE RECHERCHE DES CORDELIERS
  PARIS, Ile-de-France, France
• CS

  Catherine Sautes-Fridman, PhD (she/her/hers)

  Professor Emeritus
  CENTRE DE RECHERCHE DES CORDELIERS
  PARIS, Ile-de-France, France
• IH

  Isaias Hernandez, PHD

  Bioinformatician post doc
  UNIVERSITE LA SORBONNE
  PARIS, Ile-de-France, France
• MP

  Marina Pulido, MSc

  INSTITUT BERGONIE
  BORDEAUX, Aquitaine, France
• AB

  Alban Bessede, PHD

  EXPLICYTE
  BORDEAUX, Aquitaine, France